Contents

Volume 92 Issue 12 | JNNP December 2021

Editorial commentaries
1249 The end of the affair?  M C Kiernan

1251 Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis  H Masuda, M Moni, S Kuwabara

1252 Maximising returns: combining newborn screening with gene therapy for spinal muscular atrophy  T H Cillingwater

1253 Gial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases  H Zetterberg

Neurodegeneration
1289 Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition  B S Kraussman, T Schneider-Axmann, R Perneczky, For the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

1296 Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis  S TF Shih, M A Farrar, V Wiley, G Chambers


Cognition

1255 Diffusion and functional MRI findings and their relationship to behaviour in postconcussion syndrome: a scoping review  M Gumas, A Santos, M C Taraglia

Cerebrovascular disease
1271 Rate of, and risk factors for, white matter hyperintensity growth: a systematic review and meta-analysis with implications for clinical trial design  R Brown, A Low, H S Markus

Neurogenetics
1278 Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications  D Santacina, K Dougiamas, A Constand, D Rinaldi, A Rometti-Lacuzza, M Howes, F Clo, P Martin-Hardy, L Jornea, C Azuara, R Migliaccio, F Pasquier, P Courtaire, S Asciaccombe, M Savoie, C Bouteleau-Brenonière, J Panente, M Dida, D Hanniquin, D Wellon, the French Research Network on FTD/FTD-ALS, the PREV-DEMALS and Predict-PGRN study groups, O Collot, B Dubois, A Bricc, R Levy, S Forlani, I Le Ber

Movement disorders

Neuroimaging
1285 Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition  B S Kraussman, T Schneider-Axmann, R Perneczky, For the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

1296 Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis  S TF Shih, M A Farrar, V Wiley, G Chambers


Cognition

1255 Diffusion and functional MRI findings and their relationship to behaviour in postconcussion syndrome: a scoping review  M Gumas, A Santos, M C Taraglia

Cerebrovascular disease
1271 Rate of, and risk factors for, white matter hyperintensity growth: a systematic review and meta-analysis with implications for clinical trial design  R Brown, A Low, H S Markus

Neurogenetics
1278 Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications  D Santacina, K Dougiamas, A Constand, D Rinaldi, A Rometti-Lacuzza, M Howes, F Clo, P Martin-Hardy, L Jornea, C Azuara, R Migliaccio, F Pasquier, P Courtaire, S Asciaccombe, M Savoie, C Bouteleau-Brenonière, J Panente, M Dida, D Hanniquin, D Wellon, the French Research Network on FTD/FTD-ALS, the PREV-DEMALS and Predict-PGRN study groups, O Collot, B Dubois, A Bricc, R Levy, S Forlani, I Le Ber

Movement disorders

Neuroimaging
1285 Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition  B S Kraussman, T Schneider-Axmann, R Perneczky, For the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

1296 Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis  S TF Shih, M A Farrar, V Wiley, G Chambers


Cognition

1255 Diffusion and functional MRI findings and their relationship to behaviour in postconcussion syndrome: a scoping review  M Gumas, A Santos, M C Taraglia

Cerebrovascular disease
1271 Rate of, and risk factors for, white matter hyperintensity growth: a systematic review and meta-analysis with implications for clinical trial design  R Brown, A Low, H S Markus

Neurogenetics
1278 Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications  D Santacina, K Dougiamas, A Constand, D Rinaldi, A Rometti-Lacuzza, M Howes, F Clo, P Martin-Hardy, L Jornea, C Azuara, R Migliaccio, F Pasquier, P Courtaire, S Asciaccombe, M Savoie, C Bouteleau-Brenonière, J Panente, M Dida, D Hanniquin, D Wellon, the French Research Network on FTD/FTD-ALS, the PREV-DEMALS and Predict-PGRN study groups, O Collot, B Dubois, A Bricc, R Levy, S Forlani, I Le Ber

Movement disorders

Neuroimaging
1285 Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition  B S Kraussman, T Schneider-Axmann, R Perneczky, For the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

1296 Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis  S TF Shih, M A Farrar, V Wiley, G Chambers

<table>
<thead>
<tr>
<th>Contents</th>
<th>Volume 92 Issue 12</th>
<th>JNNP December 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Multiple sclerosis</strong></td>
<td>1319 Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy</td>
<td><strong>Neuropsychiatry</strong></td>
</tr>
<tr>
<td><strong>Migraine</strong></td>
<td>1325 Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects</td>
<td><strong>Neurological picture</strong></td>
</tr>
<tr>
<td>1335 Greater occipital nerve block modulates nociceptive signals within the trigeminocervical complex</td>
<td><strong>PostScript</strong></td>
<td>1348 Letters</td>
</tr>
<tr>
<td>J Hoffmann, J Mehnert, E M Koo, A May</td>
<td><strong>PostScript</strong></td>
<td>1348 Letters</td>
</tr>
</tbody>
</table>